Endonovo Therapeutics (ENDV) Short Interest Ratio & Short Volume

Short interest is the volume of Endonovo Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 519,100 shares of ENDV short. 0.05% of Endonovo Therapeutics' shares are currently sold short. Learn More on Endonovo Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.05% of Endonovo Therapeutics' floating shares are currently sold short.

Endonovo Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 519,100 shares, a decrease of 13.4% from the previous total of 599,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.05% of Endonovo Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "medical equipment" compare to Endonovo Therapeutics: Dalton Industries Inc. (0.04%), Arch Therapeutics, Inc. (0.15%), Non-Invasive Monitoring Systems Inc. (0.00%), Nuwellis, Inc. (76.90%), T2 Biosystems, Inc. (0.02%), Helius Medical Technologies, Inc. (372.73%), SmileDirectClub, Inc. (1.18%), G Medical Innovations Holdings Ltd (0.00%), ViewRay, Inc. (0.18%), Acutus Medical, Inc. (0.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling ENDV is an investing strategy that aims to generate trading profit from Endonovo Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Endonovo Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENDV, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENDV, twice per month. The most recent reporting period available is July, 31 2025.